Vanessa Silva-Moraes

Dr. Vanessa Silva-Moraes

University of Georgia
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Cell Reports Medicine
Verified
Journal Article
Open access
ATAlison Tarke
Alison Tarke
PRParham Ramezani-Rad
Parham Ramezani-Rad
TNTertuliano Alves Pereira Neto
Tertuliano Alves Pereira Neto
YLYeji Lee
Yeji Lee
Vanessa Silva-MoraesVanessa Silva-Moraes
Vanessa Silva-Moraes
Alessandro SetteAlessandro Sette
Alessandro Sette
Little is known about the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or SARS2) vaccine breakthrough infections (BTIs) on the magnitude and breadth of the T cell repertoire after exposure to different variants. We studied samples from individuals who experienced symptomatic BTIs during Delta or Omicron waves. In the pre-BTI samples, 30% of the donors exhibited substantial immune memory against non-S (spike) SARS2 antigens, consistent with previous undiagnosed asymptomatic SARS2 infections. Following symptomatic BTI, we observed (1) enhanced S-specific CD4 and CD8 T cell responses in donors without previous asymptomatic infection, (2) expansion of CD4 and CD8 T cell responses to non-S targets (M, N, and nsps) independent of SARS2 variant, and (3) generation of novel epitopes recognizing variant-specific mutations. These variant-specific T cell responses accounted for 9%-15% of the total epitope repertoire. Overall, BTIs boost vaccine-induced immune responses by increasing the magnitude and by broadening the repertoire of T cell antigens and epitopes recognized.


1 January 2019 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
Vanessa Silva-MoraesVanessa Silva-Moraes
Vanessa Silva-Moraes
LSLisa M Shollenberger
Lisa M Shollenberger
LSLiliane Maria Vidal Siqueira
Liliane Maria Vidal Siqueira
WCWilliam Castro-Borges
William Castro-Borges
DHDonald A Harn
Donald A Harn
PCPaulo Marcos Zech Coelho
Paulo Marcos Zech Coelho
The population of Brazil is currently characterised by many individuals harbouring low-intensity Schistosoma mansoni infections. The Kato-Katz technique is the diagnostic method recommended by the World Health Organization (WHO) to assess these infections, but this method is not sensitive enough in the context of low egg excretion. In this regard, potential alternatives are being employed to overcome the limits of the Kato-Katz technique. In the present review, we evaluated the performance of parasitological and immunological approaches adopted in Brazilian areas. Currently, the diagnostic choices involve a combination of strategies, including the utilisation of antibody methods to screen individuals and then subsequent confirmation of positive cases by intensive parasitological investigations.

1 May 2013 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
RGRafaella Fortini Queiroz e Grenfell
Rafaella Fortini Queiroz e Grenfell
WMWatson Martins
Watson Martins
MEMartin Enk
Martin Enk
AAAureo Almeida
Aureo Almeida
LSLiliane Siqueira
Liliane Siqueira
PCPaulo Marcos Zech Coelho
Paulo Marcos Zech Coelho
Schistosomiasis diagnosis is based on the detection of eggs in the faeces, which is laborious and lacks sensitivity, especially for patients with a low parasite burden. Immunological assays for specific antibody detection are available, but they usually demonstrate low sensitivity and/or specificity. In this study, two simple immunological assays were evaluated for the detection of soluble Schistosoma mansoni adult worm preparation (SWAP) and egg-specific IgGs. These studies have not yet been evaluated for patients with low parasite burdens. Residents of an endemic area in Brazil donated sera and faecal samples for our study. The patients were initially diagnosed by a rigorous Kato-Katz analysis of 18 thick smears from four different stool samples. The ELISA-SWAP was successful for human diagnosis with 90% sensitivity and specificity, confirming the Kato-Katz diagnosis with nearly perfect agreement, as seen by the Kappa index (0.85). Although the ELISA-soluble S. mansoni egg antigen was 85% sensitive, it exhibited low specificity (80%; Kappa index: 0.75) and was more susceptible to cross-reactivity. We believe that immunological assays should be used in conjunction with Kato-Katz analysis as a supplementary tool for the diagnosis of schistosomiasis for patients with low infection burdens, which are usually hard to detect.

1 August 2013 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
Vanessa Silva-MoraesVanessa Silva-Moraes
Vanessa Silva-Moraes
FCFlávia Fernanda Bubula Couto
Flávia Fernanda Bubula Couto
MVMarah Mileib Vasconcelos
Marah Mileib Vasconcelos
NANeusa Araújo
Neusa Araújo
PCPaulo Marcos Zech Coelho
Paulo Marcos Zech Coelho
RGRafaella Fortini Queiroz e Grenfell
Rafaella Fortini Queiroz e Grenfell
Current schistosomiasis control strategies are largely based on chemotherapeutic agents and a limited number of drugs are available today. Praziquantel (PZQ) is the only drug currently used in schistosomiasis control programs. Unfortunately, this drug shows poor efficacy in patients during the earliest infection phases. The effects of PZQ appear to operate on the voltage-operated Ca2+channels, which are located on the external Schistosoma mansoni membrane. Because some Ca2+channels have dihydropyridine drug class (a class that includes nifedipine) sensitivity, an in vitro analysis using a calcium channel antagonist (clinically used for cardiovascular hypertension) was performed to determine the antischistosomal effects of nifedipine on schistosomula and adult worm cultures. Nifedipine demonstrated antischistosomal activity against schistosomula and significantly reduced viability at all of the concentrations used alone or in combination with PZQ. In contrast, PZQ did not show significant efficacy when used alone. Adult worms were also affected by nifedipine after a 24 h incubation and exhibited impaired motility, several lesions on the tegument and intense contractility. These data support the idea of Ca2+channels subunits as drug targets and favour alternative therapeutic schemes when drug resistance has been reported. In this paper, strong arguments encouraging drug research are presented, with a focus on exploring schistosomal Ca2+channels.

29 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
David ForgacsDavid Forgacs
David Forgacs
Vanessa Silva-MoraesVanessa Silva-Moraes
Vanessa Silva-Moraes
Giuseppe Andrea SauttoGiuseppe Andrea Sautto
Giuseppe Andrea Sautto
HHHannah B. Hanley
Hannah B. Hanley
JGJasper L. Gattiker
Jasper L. Gattiker
TRTed Ross
Ted Ross
In order to longitudinally track SARS-CoV-2 antibody levels after vaccination or infection, we assessed anti-RBD antibody levels in over 1000 people and found no significant decrease in antibody levels during the first 14 months after infection in unvaccinated participants, however, a significant waning of antibody levels was observed following vaccination. Participants who were pre-immune to SARS-CoV-2 prior to vaccination seroconverted to higher antibody levels, which were maintained at higher levels than in previously infected, unvaccinated participants. Older participants exhibited lower level of antibodies after vaccination, but a higher level after infection than younger people. The rate of antibody waning was not affected by pre-immunity or age. Participants who received a third dose of an mRNA vaccine not only increased their antibody levels ~14-fold, but also had ~3 times more antibodies compared to when they received their primary vaccine series. PBMC-derived memory B cells from 13 participants who lost all circulating antibodies were differentiated into antibody secreting cells (ASCs). There was a significant recall of memory B cell ASCs in the absence of serum antibodies in 5–8 of the 10 vaccinated participants, but not in any of the 3 infected participants, suggesting a strong connection between antibody levels and the effectiveness of memory B cell recall.